24 related articles for article (PubMed ID: 32505632)
1. Prognostic significance of SIRI in patients with late-stage lung adenocarcinoma receiving EGFR-TKI treatment.
Wang H; Li W
Curr Probl Cancer; 2024 Jun; 50():101099. PubMed ID: 38723294
[TBL] [Abstract][Full Text] [Related]
2. Stroke as initial manifestation of non-small cell lung cancer with Trousseau syndrome.
Hong W; Zhang T; Shan C; Li H; Lin T; Liu D; Zhen J; Li J; Lai M; Zhou Z; Zhou C; Zhou M; Wang M; Cai L; Wen L
BMC Cancer; 2023 Nov; 23(1):1096. PubMed ID: 37950224
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.
Yang G; Kim KH; Lee CG; Hong MH; Kim HR; Cho Y; Yoon HI
Cancer Res Treat; 2024 Jan; 56(1):115-124. PubMed ID: 37641819
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of stage Ib lung adenocarcinoma with postoperative brain oligometastasis: a case report and literature review.
Xu K; Feng X; Wang L; Du Q; Jin E
Folia Neuropathol; 2024; 62(1):108-112. PubMed ID: 38174674
[TBL] [Abstract][Full Text] [Related]
5. Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
Ederhy S; Cadranel J; Granger C; Hammoudi N
Lancet; 2024 Mar; 403(10429):860-861. PubMed ID: 38431352
[No Abstract] [Full Text] [Related]
6. Prognostic factors affecting survival in patients with non-small cell lung cancer treated with salvage surgery after drug therapy: a multi-institutional retrospective study.
Suzuki S; Asakura K; Okui M; Izawa N; Sawafuji M; Sakamaki H; Shigenobu T; Tajima A; Oka N; Masai K; Kaseda K; Hishida T; Yasuda H; Fukunaga K; Asamura H
World J Surg Oncol; 2023 Sep; 21(1):290. PubMed ID: 37715273
[TBL] [Abstract][Full Text] [Related]
7. Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment.
Jang YJ; Hyun DG; Ji W; Choi CM; Yoon S; Lee DH; Kim SW; Lee JC
Cancer Res Treat; 2023 Apr; 55(2):468-478. PubMed ID: 36470259
[TBL] [Abstract][Full Text] [Related]
8. Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.
Yu X; Chu X; Wu Y; Zhou J; Zhao J; Zhou F; Han C; Su C
Cancer Drug Resist; 2021; 4(3):728-739. PubMed ID: 35582303
[No Abstract] [Full Text] [Related]
9. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Miyawaki T; Kenmotsu H; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
BMC Cancer; 2021 Nov; 21(1):1247. PubMed ID: 34798865
[TBL] [Abstract][Full Text] [Related]
10. Detailed Analysis and Radiomic Prediction of First Progression Sites of First-Line Targeted Therapy for EGFR-Mutant Lung Adenocarcinoma Patients With Systemic Metastasis.
Li X; Hou R; Yu W; Zhu X; Li H; Yang Y; Qian D; Fu X
Front Oncol; 2021; 11():757892. PubMed ID: 34676174
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
Garg A; Batra U; Choudhary P; Jain D; Khurana S; Malik PS; Muthu V; Prasad KT; Singh N; Suri T; Mohan A
Curr Probl Cancer; 2020 Jun; 44(3):100570. PubMed ID: 32498966
[TBL] [Abstract][Full Text] [Related]
12. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
13. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.
Li XY; Zhu XR; Zhang CC; Yu W; Zhang B; Shen TL; Zhang HY; Fu XL
Clin Lung Cancer; 2020 Nov; 21(6):534-544. PubMed ID: 32505632
[TBL] [Abstract][Full Text] [Related]
15. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.
Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630
[TBL] [Abstract][Full Text] [Related]
16. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
